DE602005026706D1 - Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung - Google Patents

Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung

Info

Publication number
DE602005026706D1
DE602005026706D1 DE602005026706T DE602005026706T DE602005026706D1 DE 602005026706 D1 DE602005026706 D1 DE 602005026706D1 DE 602005026706 T DE602005026706 T DE 602005026706T DE 602005026706 T DE602005026706 T DE 602005026706T DE 602005026706 D1 DE602005026706 D1 DE 602005026706D1
Authority
DE
Germany
Prior art keywords
humanized col
antibodies
disclosed
col
frame
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026706T
Other languages
English (en)
Inventor
Syed Kashmiri
Jeffrey Schlom
Eduardo Padlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Government filed Critical US Government
Publication of DE602005026706D1 publication Critical patent/DE602005026706D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602005026706T 2004-12-30 2005-12-30 Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung Active DE602005026706D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64067204P 2004-12-30 2004-12-30
PCT/US2005/047431 WO2006074071A1 (en) 2004-12-30 2005-12-30 Framework residue substituted humanized col-1 antibodies and their use

Publications (1)

Publication Number Publication Date
DE602005026706D1 true DE602005026706D1 (de) 2011-04-14

Family

ID=36216923

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026706T Active DE602005026706D1 (de) 2004-12-30 2005-12-30 Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung

Country Status (7)

Country Link
US (2) US7855276B2 (de)
EP (1) EP1833850B9 (de)
AT (1) ATE500276T1 (de)
AU (1) AU2005322869B2 (de)
CA (1) CA2593693A1 (de)
DE (1) DE602005026706D1 (de)
WO (1) WO2006074071A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737597C (en) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2011159835A1 (en) 2010-06-16 2011-12-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
US8771687B2 (en) 2010-12-02 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds GRP94
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
CA3022765A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
KR20200030029A (ko) 2017-05-02 2020-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
TW202100550A (zh) 2019-03-03 2021-01-01 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CN113393899A (zh) * 2021-05-26 2021-09-14 江苏普瑞康生物医药科技有限公司 基于动态规划的抗体人源化的方法与装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
CA2348698C (en) 1998-10-31 2012-01-03 Syed V. S. Kashmiri Variants of humanized anti-carcinoma monoclonal antibody cc49
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AU2003270369A1 (en) 2002-09-05 2004-03-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same

Also Published As

Publication number Publication date
CA2593693A1 (en) 2006-07-13
AU2005322869B2 (en) 2011-05-12
US8828717B2 (en) 2014-09-09
ATE500276T1 (de) 2011-03-15
EP1833850B1 (de) 2011-03-02
WO2006074071A8 (en) 2006-09-14
US20080274055A1 (en) 2008-11-06
EP1833850B9 (de) 2011-05-18
US20110053264A1 (en) 2011-03-03
AU2005322869A1 (en) 2006-07-13
US7855276B2 (en) 2010-12-21
WO2006074071A1 (en) 2006-07-13
EP1833850A1 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
DE602005026706D1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2007092939A3 (en) Antigenic gm-csf peptides and antibodies to gm-csf
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
DE60329823D1 (de) Antikörper mit t-zell-rezeptor-artiger spezifität, aber höherer affinität und seine verwendung zum nachweis und zur behandlung von krebs, virusinfektionen und autoimmunkrankheiten
WO2010043977A3 (en) Dengue virus neutralizing antibodies and uses thereof
MX2009012493A (es) Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
DE60334364D1 (de) Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
EA202091901A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
DE60239454D1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
SG170793A1 (en) Anti-mn antibodies and methods of using same
UA92504C2 (en) Anti-myostatin monoclonal antibody
UA85058C2 (ru) Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir)
JP2017508475A5 (de)
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition